Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Conmed ( (CNMD) ) just unveiled an update.
On September 8, 2025, CONMED Corporation announced the appointment of Kim Kelderman to its Board of Directors. Mr. Kelderman, who has extensive experience in the life sciences sector, will serve on the Corporate Governance and Nominating Committee and the Strategy Committee. His previous roles include President and CEO of Bio-Techne and leadership positions at Thermo Fisher Scientific and Becton Dickinson. This strategic appointment is expected to enhance CONMED’s board with Mr. Kelderman’s global leadership experience and insights, supporting the company’s long-term vision and stakeholder value delivery.
The most recent analyst rating on (CNMD) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.
Spark’s Take on CNMD Stock
According to Spark, TipRanks’ AI Analyst, CNMD is a Outperform.
Conmed’s overall stock score of 78 reflects its strong financial performance and positive earnings outlook. The company’s attractive valuation and moderate technical indicators further support its potential for growth. While challenges exist in specific market segments, the company’s strategic initiatives and product strengths position it well for future expansion.
To see Spark’s full report on CNMD stock, click here.
More about Conmed
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The company’s products are used by surgeons and other healthcare professionals in specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
Average Trading Volume: 461,948
Technical Sentiment Signal: Sell
Current Market Cap: $1.7B
See more data about CNMD stock on TipRanks’ Stock Analysis page.